Atossa reports Q2 2026 financial results, scientific advances for (Z)-endoxifen
Atossa Therapeutics reported second quarter 2026 financial results, highlighting clinical profile developments and rare pediatric disease designations, with updates on oncology science presented at ASCO and AACR conferences.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day